Novonesis Analyst Upgrades: Target Prices Rise to 480–490 DKK
Novonesis analysts lift target prices—Jefferies, BørsHus and Deutsche Bank now forecast up to 490 kr, backing a bullish stance amid modest share gains.
One minute to read
Dr. Sarah Winters
Medical Affairs Correspondent
Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.
AI Author, more information here
Danaher Corp Dividend‑Reinvestment Event: Cash vs. Security Choice for Investors
Danaher Corp dividend‑reinvestment event: choose cash or reinvest in more shares—clear options, timelines, and settlement details for investors and brokers.
2 minutes to read
Coloplast Shares Dip as Medical‑Device Sector Slides – Market Insight & Investor Takeaway
Coloplast’s share dip mirrors a small sector‑wide decline in Denmark’s medical‑device market, showing cautious investor sentiment but no operational change.
2 minutes to read
Merck’s Stock Rises as Investors Shift to Defensive Healthcare Amid Geopolitical Stability
Merck’s stock climbs as investors favor defensive healthcare amid easing geopolitics and oil volatility, showing robust earnings and a resilient pipeline.
2 minutes to read
Humm Group’s Board Pause & ASIC Review: Key Governance & Takeover Insights for Investors
Humm Group’s board seat remains vacant as ASIC completes investigations, highlighting the firm’s focus on AI governance, breach protocols, and fair loan terms.
3 minutes to read
Genmab’s Epcoritamab + Lenalidomide Shines in Phase 3 DLBCL‑4 Trial, Boosting Progression‑Free Survival
Genmab’s Phase 3 EPCORE DLBCL‑4 trial shows epcoritamab + lenalidomide cuts progression risk by ~60 % in relapsed/refractory DLBCL, with a manageable safety profile and potential for broader use.
4 minutes to read
Pro Medicus Ltd: Strong Technical Momentum & Institutional Confidence in Australian Healthcare Tech
Pro Medic Ltd. attracts tech‑savvy investors and clinical users alike—its diagnostics software boosts accuracy, safety, and workflow while driving strong ASX momentum.
3 minutes to read
Danaher’s 10‑Year Share‑Price Surge + $1M Ebola Aid: Growth Meets Global Impact
Danaher’s decade‑long share‑price surge (+112%) proves long‑term investor value, while its $1 M Ebola aid showcases how corporate expertise fuels global health impact.
3 minutes to read
How Bayer’s Supreme Court Win Lowers Litigation Risk and Fuels Shareholder Confidence
Supreme Court ruling cuts Bayer’s glyphosate litigation risk, boosting shares and analyst targets. Still, debt, cash flow, and upcoming product approvals shape investor outlook.
3 minutes to read
Join Cigna Group’s 30th AGM on July 22: Secure Remote Voting, Live Access & Full Annual Report
Discover how Cigna Group’s 30th AGM will transform shareholder engagement with secure video‑conference voting, real‑time transparency, and easy access to FY‑2026 reports.
2 minutes to read